Brain-Health Company IXICO Ready To Seize Pharma's Digital Health Opportunities
Brain-health company IXICO is ready to seize pharma's digital health opportunities by expanding into the companion digital health product sector. Last year the company partnered with Biogen to pilot its digital platform Assessa with the drug TYSABRI.
You may also be interested in...
Brain health imaging company IXICO has outlined a five-point plan to scale business in a bid to deliver double digit revenue growth. With a new CEO at the helm, the UK company is looking to expand its network of pharma partners, increase its penetration of the clinical trials market and target later-stage clinical phases with its digital technologies.
IXICO has struck a partnership with a major pharma player to help improve clinical outcomes of the latter’s blockbuster drug for multiple sclerosis – which will hopefully lead to increased sales – by adding the use of IXICO’s Assessa digital brain health monitoring technology to better manage a serious and potentially fatal side effect of the therapy.
Experts from the University of Chicago are advocating for helmet ventilation for COVID-19 patients. Medtech Insight spoke to acute nurse practitioner Aurika Savickaite who is helping lead an initiative to educate and raise awareness of the technology.